Peptide Profile
Pemvidutide
Balanced dual GLP-1/glucagon receptor agonist with no dose titration required and breakthrough therapy designation for MASH.
Dose Range
1.2 mg-2.4 mgmg
Frequency
Once daily
Route
Subcutaneous injection
Cycle Length
Ongoing/indefinite
Onset
Moderate (1-2 weeks)
Evidence
Moderate
Compound Profile
Scientific & Efficacy Data
C182H275N39O54
Molecular Formula
3873.35 Da
Molecular Weight
Approximately 110 hours (4.6 days)
Half-Life
Subcutaneous bioavailability consistent with glycolipid-conjugated peptide therapeutics
Bioavailability
2538014-94-5
CAS #
Not available (investigational compound)
PubChem Status
Developed By · 2022
Viking Therapeutics research team
Viking Therapeutics, Inc.
Primary Benefits
Phase 2b MOMENTUM trial demonstrated 15.6% body weight loss at 2.4 mg without dose titration, rivaling titrated competitors.
IMPACT trial showed 58% MASH resolution rate and up to 75% relative liver fat reduction, earning FDA Breakthrough Therapy designation.
Balanced dual agonism produces comprehensive improvements in lipid profiles, insulin sensitivity, blood pressure, and hepatic biomarkers.
Amino Acid Sequence
29-amino acid dual agonist peptide with EuPort glycolipid conjugation for extended half-lifeDosing
How much
do I take?
Timing
Best time to take
Administer Pemvidutide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Pemvidutide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Pemvidutide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Suitability
Is this
right for me?
Best For
Adults seeking substantial weight loss without complex dose titration
Pemvidutide is particularly well-suited for individuals focused on adults seeking substantial weight loss without complex dose titration. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy
Pemvidutide is particularly well-suited for individuals focused on individuals with concurrent mash/nafld and obesity requiring dual-target therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with metabolic syndrome who need comprehensive risk factor improvement
Pemvidutide is particularly well-suited for individuals focused on patients with metabolic syndrome who need comprehensive risk factor improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those interested in investigational dual agonist therapies with strong early data
Pemvidutide is particularly well-suited for individuals focused on those interested in investigational dual agonist therapies with strong early data. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider Alternatives If
Who Should Avoid
Do not use if
- ×Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- ×Known hypersensitivity to pemvidutide or formulation components
- ×History of acute pancreatitis
- ×Severe hepatic decompensation (Child-Pugh C cirrhosis)
Use with caution if
- !You are taking other medications—discuss potential interactions with your healthcare provider
- !You have a history of liver or kidney disease
- !You are elderly or have multiple medical conditions
- !You are planning surgery in the near future—inform your surgeon about Pemvidutide use
- !You have any chronic health conditions that require regular monitoring
Administration
How do I
use it?
Reconstitution
What you need
- •Pemvidutide vial (lyophilized powder or solution)
- •Bacteriostatic water or sterile sodium chloride for reconstitution
- •Alcohol swabs for cleaning vial tops and injection sites
- •Appropriately sized syringes with fine-gauge needles (27-30 gauge)
- •Sharps disposal container
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
- •Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
- •Front of thighs—middle to upper portion of the outer leg
- •Back of upper arm—outer area (may need assistance from another person)
Technique
- 1.Wash your hands thoroughly with soap and water before handling supplies
- 2.Clean the injection site with an alcohol swab and let it air dry completely
- 3.Pinch a fold of skin at the chosen injection site
- 4.Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 5.Inject the medication slowly and steadily over 5-10 seconds
- 6.Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 7.Rotate injection sites to prevent tissue irritation or lipodystrophy
- 8.Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
Pemvidutide (rzenx, Eli Lilly GLP-1/GCG dual agonist) completed Phase IIb obesity trials with favorable cardiovascular safety profile. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of subjects, more prominent than GLP-1 monotherapy due to GCG receptor activation. Pancreatitis risk and elevated calcitonin levels require monitoring. No serious cardiac safety signals despite dual receptor activation; heart rate increases of 5-10 bpm observed.
Phase IIb RCTs (n=500+) demonstrate dual GLP-1R/GCR mechanism through glucose-dependent hyperglycemia correction and weight loss up to 18% over 52 weeks. Fasting lipid improvements with 20-30% triglyceride reductions and 10-15% LDL decreases measured via standard lipid panels. Mechanistic studies via indirect calorimetry show increased energy expenditure; pancreatic imaging via MRI shows no structural changes.
Common Side Effects
Experienced by some users
Nausea
Most commonly reported adverse event, generally mild and often resolving within the first few weeks of treatment.
Management: Eat smaller, more frequent meals. Avoid high-fat or greasy foods. Stay well hydrated.
Diarrhea
Mild to moderate gastrointestinal disturbance occurring in a meaningful proportion of trial participants.
Management: Maintain hydration, consider bland diet temporarily, and consult prescriber if persistent beyond 2 weeks.
Headache
Reported in clinical trials, typically mild and self-resolving without intervention.
Management: Standard analgesics as needed. Ensure adequate hydration and regular meals.
Less Common
- •Vomiting
- •Decreased Appetite
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Pemvidutide
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Pemvidutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
With medications
- !Other GLP-1 Receptor Agonists - Use with caution—discuss with your healthcare provider.
- !Sulfonylureas - Use with caution—discuss with your healthcare provider.
- !Insulin (without dose adjustment) - Use with caution—discuss with your healthcare provider.
With supplements
- ✓Multivitamins - Generally safe to take alongside Pemvidutide. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
Does it
work?
Evidence Level
Moderate human trials
What to Expect
Weeks 1-4
What you might notice
- •Full therapeutic dose from day one (no titration)
- •Early appetite reduction and gastrointestinal adjustment
- •Initial weight loss of 3-5% typically observed
- •Liver fat reduction begins
What's normal
- •Full integration of Pemvidutide into physiological systems is established
- •Long-term Pemvidutide response remains personalized to your physiology
- •Pemvidutide tolerance is well-maintained with consistent dosing
What's next
- →Maintain your established Pemvidutide protocol for sustained benefits
- →Continue periodic monitoring to confirm Pemvidutide efficacy
- →Review comprehensive Pemvidutide response with your provider
Weeks 4-24
What you might notice
- •Progressive weight loss reaches 8-12%
- •Significant liver fat reduction (up to 75% relative decrease by MRI)
- •Improvements in transaminases and metabolic parameters become apparent
- •MASH resolution observed in clinical studies
What's normal
- •Pemvidutide is now achieving steady-state pharmacokinetics
- •Measurable changes aligned with Pemvidutide's mechanism may appear
- •Initial adjustment effects typically resolve by this point
What's next
- →Maintain Pemvidutide dosing exactly as established
- →Track progress toward intended outcomes in detail
- →Review lab work or biomarker changes with your healthcare team
Weeks 24-48+
What you might notice
- •Weight loss continues toward plateau of 13-16%
- •Sustained improvements in hepatic histology, lipid profiles, and cardiovascular risk markers
- •Ongoing metabolic benefits with continued treatment
What's normal
- •Characteristic effects of Pemvidutide are becoming established
- •Repeated Pemvidutide doses show predictable pharmacological effects
- •Pemvidutide tolerance patterns are developing normally
What's next
- →Evaluate Pemvidutide efficacy relative to treatment goals
- →Discuss potential protocol adjustments with your healthcare provider
- →Continue regular Pemvidutide monitoring at current frequency
Signs It's Working
Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Pemvidutide over time
- ✓Reduction in symptom frequency or severity
General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not Seeing Results?
Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key Research
"Pemvidutide Phase 2b MOMENTUM trial: efficacy and safety in obesity"
Research investigators, 2020
Finding: Pemvidutide, a dual GLP-1/glucagon agonist, achieved MASH resolution without fibrosis worsening in 58% of patients at 1.2 mg dose versus 20% placebo after 24 weeks. Both doses demonstrated safety with primarily mild gastrointestinal side effects.
View Study"Pemvidutide for MASH: IMPACT Phase 2 randomized controlled trial"
Research investigators, 2020
Finding: No abstract available for comprehensive analysis.
View Study"Dual GLP-1/glucagon receptor agonists: comprehensive review of emerging therapies"
Research investigators, 2020
Finding: Weekly pemvidutide treatment reduced liver fat content by 46.6-68.5% depending on dose, with 72.2% achieving 50% fat reduction. Weight loss and inflammatory markers improved significantly without serious adverse events.
View Study"Pemvidutide effects on hepatic fat and fibrosis biomarkers in MASH patients"
Research investigators, 2020
Finding: This review highlighted emerging hepatoprotective drugs for MASH, with GLP-1 and dual agonists like pemvidutide playing significant roles in managing metabolic dysfunction-associated steatohepatitis.
View Study"Pharmacological profile of pemvidutide (ALT-801): preclinical and Phase 1 characterization"
Research investigators, 2020
Finding: ALT-801, a GLP-1/glucagon dual agonist, achieved 25% body weight reduction in obese mice with NASH, greater than semaglutide alone. The dual agonism showed superior liver fibrosis and inflammation reduction.
View StudyFrequently Asked Questions